Ramsey C C, Burney D P, Macintire D K, Finn-Bodner S
Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana 61801, USA.
J Am Vet Med Assoc. 1996 Aug 15;209(4):780-5.
Four dogs with thrombosis were referred for diagnostic testing and were subsequently treated by the use of streptokinase. The range of duration of clinical signs associated with thrombosis was 6 to 120 days. Causes of thrombosis were heart disease (1 dog), protein-losing nephropathy and hyperadrenocorticism (1), hyperadrenocorticism (1), and idiopathic (1). Possible factors that predisposed dogs to hypercoagulability included hypertension (2 dogs) and diabetes mellitus (1). All dogs were treated for underlying disease by use of supportive care. The first dog was treated with a loading dose of 250,000 U of streptokinase, i.v., with a subsequent maintenance dosage of 100,000 U/h, i.v., and also was treated with anticoagulant. The subsequent 3 dogs were treated with a loading dose of 90,000 U of streptokinase, i.v., and maintenance dosage of 45,000 U/ h, i.v., at various intervals. These dogs also were treated with anticoagulant. Three dogs had minor hemorrhage as an adverse effect to streptokinase infusion, but they did not require treatment for the hemorrhage. Complete resolution of the thrombus was observed in 3 dogs, and partial resolution of the thrombus was observed in the other dog. In all dogs, partial or complete resolution of clinical signs associated with thrombosis was seen. Streptokinase may be an effective treatment for dogs with thrombosis.
4只患有血栓形成的犬被转诊进行诊断性检测，随后接受链激酶治疗。与血栓形成相关的临床症状持续时间为6至120天。血栓形成的原因包括心脏病（1只犬）、蛋白丢失性肾病和肾上腺皮质功能亢进（1只）、肾上腺皮质功能亢进（1只）以及特发性（1只）。使犬易发生高凝状态的可能因素包括高血压（2只犬）和糖尿病（1只）。所有犬均通过支持性护理治疗基础疾病。第一只犬静脉注射250,000 U链激酶的负荷剂量，随后静脉维持剂量为100,000 U/h，同时还接受了抗凝治疗。随后的3只犬静脉注射90,000 U链激酶的负荷剂量，静脉维持剂量为45,000 U/h，给药间隔不同。这些犬也接受了抗凝治疗。3只犬出现轻微出血作为链激酶输注的不良反应，但它们的出血无需治疗。3只犬血栓完全溶解，另一只犬血栓部分溶解。所有犬均出现与血栓形成相关的临床症状部分或完全缓解。链激酶可能是治疗犬血栓形成的有效方法。
